1. Our dynamic pipeline showcases the versatility and potential of our cutting-edge platform technology. Anchored in a robust foundation, our pipeline boasts four distinct assets, each at varying stages of development, yet all derived from the same platform. This unified approach allows us to leverage the inherent strengths of our technology across multiple therapeutic avenues. From early-stage research to mid/late clinical development, our pipeline represents a comprehensive spectrum of possibilities, promising breakthroughs in diverse areas of application.


  1. PRV111 is planned to be studied in a Phase 3 clinical trial in oral Carcinoma in Situ.


An Accelerated & De-risked Pipeline Via 505(b)2 Regulatory Pathway

Contact Us
close slider

Contact Us